<DOC>
	<DOCNO>NCT02275338</DOCNO>
	<brief_summary>To assess efficacy Lanreotide Autogel 120 mg relief vomit due inoperable malignant intestinal obstruction patient without nasogastric tube ( NGT ) ass efficacy lanreotide Autogel 120 mg removal nasogastric tube without recurrence vomit patient inoperable malignant intestinal obstruction nasogastric tube .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Lanreotide Autogel 120 MG Treatment Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Obstruction</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Written inform consent study related procedure Male female patient age 18 year old time enrollment Diagnosis intestinal obstruction malignant origin In case peritoneal carcinomatosis , confirmation CT MRI scan within 3 month precede inclusion study Confirmed inoperable surgical advice Patient nasogastric tube OR present 3 episode vomit / 24h last 48 hour Estimated life expectancy 1 month Operable obstruction subobstruction Bowel obstruction due nonmalignant cause Signs bowel perforation Prior treatment somatostatin analogue within previous 60 day A known hypersensitivity study treatment related compound Previous participation study Is likely require treatment study drug permit study protocol Has abnormal baseline finding , medical condition ( ) laboratory finding , opinion Investigator , might jeopardise subject 's safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>